Prescribing opioids in primary care: Safely starting, monitoring, and stopping

Cleveland Clinic Journal of Medicine

Volumn 83, Issue 3, 2016, Pages 207-215

  Tobin, Daniel G ^a,b   Andrews, Rebecca ^c,d   Becker, William C ^a,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

CHRONIC PAIN; DRUG MONITORING; HUMAN; PRESCRIPTION; PRIMARY HEALTH CARE; PROCEDURES; SAFETY; STANDARDS;

ANALGESICS, OPIOID; CHRONIC PAIN; DRUG MONITORING; DRUG PRESCRIPTIONS; HUMANS; PRIMARY HEALTH CARE; SAFETY;

EID: 84973359567     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.83a.15034     Document Type: Review

References (45)

1. Institute of Medicine of the National Academies. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. http://iom.nationalacademies.org/reports/2011/relieving-pain-in-america-a-blueprint-for-transforming-prevention-care-education-research.aspx. Accessed February 8, 2016
2. McCarberg BH, Nicholson BD, Todd KH, Palmer T, Penles L. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther 2008; 15:312-320
3. Roehr B. US needs new strategy to help 116 million patients in chronic pain. BMJ 2011; 343:d4206
4. Breuer B, Pappagallo M, Tai JY, Portenoy RK. US board-certified pain physician practices: uniformity and census data of their locations. J Pain 2007; 8:244-250
5. Paulozzi L, Dellinger A, Degutis L. Lessons from the past. Inj Prev 2012; 18:70
6. US Department of Health and Human Services; Substance Abuse and Mental Health Services Administration. Results from the 2013 national survey on drug use and health: Summary of national findings, NSDUH series H-48, HHS publication no. (SMA) 14-4863. www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.htm. Accessed February 8, 2016
7. Bronstein K, Passik S, Munitz L, Leider H. Can clinicians accurately predict which patients are misusing their medications? J Pain 2011; 12(suppl):P3
8. Von Korff M, Kolodny A, Deyo RA, Chou R. Long-term opioid therapy reconsidered. Ann Intern Med 2011; 155:325-328
9. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:276-286
10. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-130
11. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004; 112:65-75
12. Compton PA, Wu SM, Schieffer B, Pham Q, Naliboff BD. Introduction of a self-report version of the prescription drug use questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage 2008; 36:383-395
13. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med 2005; 6:432-442
14. Chen JT, Fagan MJ, Diaz JA, Reinert SE. Is treating chronic pain torture? Internal medicine residents' experience with patients with chronic nonmalignant pain. Teach Learn Med 2007; 19:101-105
15. Gallagher RM. Empathy: a timeless skill for the pain medicine toolbox. Pain Med 2006; 7:213-214
16. Woolf CJ; American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140:441-451
17. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6:107-112
18. Medscape. A guide to state opioid prescribing policies resource center news. www.medscape.com/index/list_5657_1. Accessed February 8, 2016
19. Penko J, Mattson J, Miaskowski C, Kushel M. Do patients know they are on pain medication agreements? Results from a sample of high-risk patients on chronic opioid therapy. Pain Med 2012; 13:1174-1180
20. McGee S, Silverman RD. Treatment agreements, informed consent, and the role of state medical boards in opioid prescribing. Pain Med 2015; 16:25-29
21. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010; 170:1968-1976
22. Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev 2007; 11:35-46
23. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315-1321
24. Smith HS. Variations in opioid responsiveness. Pain Physician 2008; 11:237-248
25. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 2010; 56:514-517
26. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18(suppl 4):S3-S13
27. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387-395
28. 107th Congress Public Law 77. US Government Printing Office. Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act, 2002. https://www.gpo.gov/fdsys/pkg/PLAW-107publ77/html/PLAW-107publ77.htm. Accessed February 8, 2016
29. Missouri Prescription Drug Monitoring Program NOW Coalition. http://mopdmpnow.org/. Accessed February 8, 2016
30. Prescription Drug Monitoring Program Center of Excellence at Brandeis. www.pdmpexcellence.org/sites/all/pdfs/Briefing%20on%20PDMP%20Effectiveness%203rd%20revision.pdf. Accessed February 8, 2016
31. Centers for Medicare and Medicaid Services. Tamper Resistant Prescriptions. www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/FraudAbuseforProfs/TRP.html. Accessed February 8, 2016
32. Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T 2012; 37:412-418
33. Starrels JL, Becker WC, Weiner MG, Li X, Heo M, Turner BJ. Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med 2011; 26:958-964
34. Herring C, Muzyk AJ, Johnston C. Interferences with urine drug screens. J Pharm Pract 2011; 24:102-108
35. Thermo Fisher Scientific. Cedia opiate 2K drugs of abuse assays. http://www.thermoscientific.com/en/product/cedia-opiate-2k-drugs-abuse-assays.html. Accessed February 8, 2016
36. Markway EC, Baker SN. A review of the methods, interpretation, and limitations of the urine drug screen. Orthopedics 2011; 34:877-881
37. Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol 2014; 38:387-396
38. Standridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician 2010; 81:635-640
39. National Highway Traffic Safety Administration. Drugs and human performance fact sheet. www.nhtsa.gov/staticfiles/nti/pdf/809725-DrugsHumanPerformFS.pdf. Accessed February 8, 2016
40. US Department of Health and Human Services; Centers for Medicare and Medicaid Services. Partners in Integrity: What is the Prescriber's Role in Preventing the Diversion of Prescription Drugs. www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Provider-Education-Toolkits/Downloads/prescriber-role-drugdiversion.pdf. Accessed February 8, 2016
41. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009; 12:679-684
42. US Department of Health and Human Services; Agency for Healthcare Research and Quality (AHRQ); National Guideline Clearinghouse. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid therapy. www.guideline.gov/content.aspx?id=23792. Accessed February 8, 2016
43. Department of Veterans Affairs/Department of Defense. Tapering and discontinuing opioids factsheet. www.healthquality.va.gov/guidelines/Pain/cot/OpioidTaperingFactSheet23May2013v1.pdf. Accessed February 8, 2016
44. US Department of Justice Drug Enforcement Administration: Office of Diversion Control. Title 21 Code of Federal Regulations, Part 1306, Section 1306.04. Purpose of issue of prescription. www.deadiversion.usdoj.gov/21cfr/cfr/1306/1306_04.htm. Accessed February 8, 2016
45. Kübler-Ross E, Wessler S, Avioli LV. On death and dying. JAMA 1972; 221:174-179